 Connection
John Imig to Enzyme Inhibitors
This is a "connection" page, showing publications John Imig has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.194 |
|
|
|
-
Hye Khan MA, Kolb L, Skibba M, Hartmann M, Bl?cher R, Proschak E, Imig JD. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 10; 61(10):2235-2246.
Score: 0.537
-
Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006 Sep; 318(3):1307-14.
Score: 0.232
-
Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev. 2006; 24(2):169-88.
Score: 0.225
-
Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005 Dec; 46(6):842-8.
Score: 0.224
-
Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochem Pharmacol. 2022 01; 195:114866.
Score: 0.169
-
Kopkan L, Huskov? Z, Sporkov? A, Varcabov? ?, Honetschl?gerov? Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, B?rgelov? M, Vojt?kov? A, Kujal P, Vernerov? Z, Cervenka L. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 2012; 35(6):595-607.
Score: 0.089
-
Honetschl?gerov? Z, Sporkov? A, Kopkan L, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Ch?bov? VC, Tesar V, Cervenka L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011 Aug; 29(8):1590-601.
Score: 0.083
-
Honetschl?gerov? Z, Huskov? Z, Vanourkov? Z, Sporkov? A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011 Jan 01; 589(Pt 1):207-19.
Score: 0.079
-
Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct; 8(10):794-805.
Score: 0.073
-
Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009 Sep; 297(3):F740-8.
Score: 0.072
-
Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009 Jun; 174(6):2086-95.
Score: 0.071
-
Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009 Jan; 116(1):61-70.
Score: 0.069
-
Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb; 4(2):165-74.
Score: 0.065
-
Ch?bov? VC, Kramer HJ, Vaneckov? I, Vernerov? Z, Eis V, Tesar V, Skaroupkov? P, Thumov? M, Schejbalov? S, Huskov? Z, Vanourkov? Z, Kolsk? A, Imig JD, Cervenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007 Aug-Sep; 47(2-3):145-59.
Score: 0.062
-
Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765.
Score: 0.031
-
Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28; 57(16):6965-72.
Score: 0.026
-
Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97.
Score: 0.024
-
Honetschl?gerov? Z, Kitada K, Huskov? Z, Sporkov? A, Kopkan L, B?rgelov? M, Varcabov? ?, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Cervenka L. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013 Feb; 31(2):321-32.
Score: 0.023
-
Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct; 301(4):F765-72.
Score: 0.021
-
Sporkov? A, Kopkan L, Varcabov? S, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1468-75.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|